Apolipoprotein E4 Allele and Gait Performance in Mild Cognitive Impairment: Results From the Gait and Brain Study

Ryota Sakurai, Manuel Montero-Odasso, Ryota Sakurai, Manuel Montero-Odasso

Abstract

Background: The apolipoprotein E polymorphism ε4 allele (ApoE4) and gait impairment are both known risk factors for developing cognitive decline and dementia. However, it is unclear the interrelationship between these factors, particularly among older adults with mild cognitive impairment (MCI) who are considered as prodromal for Alzheimer's disease. This study aimed to determine whether ApoE4 carrier individuals with MCI may experience greater impairment in gait performance.

Methods: Fifty-six older adults with MCI from the "Gait and Brain Study" who were identified as either ApoE4 carriers (n = 20) or non-ApoE4 carriers (n = 36) with 1 year of follow-up were included. Gait variability, the main outcome variable, was assessed as stride time variability with an electronic walkway. Additional gait variables and cognitive performance (mini-mental state examination [MMSE] and Montreal Cognitive Assessment [MoCA]) were also recorded. Covariates included age, sex, education level, body mass index, and number of comorbidities.

Results: Baseline characteristics were similar for both groups. Repeated measures analysis of covariance showed that gait stride time and stride length variabilities significantly increased in ApoE4 carriers but was maintained in the non-ApoE4 carriers. Similarly, ApoE4 carriers showed greater decrease in MMSE score at follow-up.

Conclusions: In this sample of older adults with MCI, the presence of at least one copy of ApoE4 was associated with the development of both increased gait variability and cognitive decline during 1 year of follow-up. ApoE4 genotype might be considered as a potential mediator of decline in mobility function in MCI; future studies with larger samples are needed to confirm our preliminary findings.

Keywords: Apolipoprotein E; Cognition; Gait variability; Longitudinal study; Mild cognitive impairment.

© The Author 2017. Published by Oxford University Press on behalf of The Gerontological Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Figures

Figure 1.
Figure 1.
Comparisons of gait variables at baseline and 1-year follow-up for ApoE4 carriers and non-ApoE4 carriers.
Figure 2.
Figure 2.
Comparisons of cognitive measurements at baseline and 1-year follow-up for ApoE4 carriers and non-ApoE4 carriers.

References

    1. Petersen RC. Mild cognitive impairment as a diagnostic entity. J Intern Med. 2004;256:183–194. doi:10.1111/j.1365-2796.2004.01388.x
    1. Montero-Odasso M, Oteng-Amoako A, Speechley M, et al. The motor signature of mild cognitive impairment: results from the gait and brain study. J Gerontol A Biol Sci Med Sci. 2014;69:1415–1421. doi:10.1093/gerona/glu155
    1. Verghese J, Annweiler C, Ayers E, et al. Motoric cognitive risk syndrome: multicountry prevalence and dementia risk. Neurology. 2014;83:718–726. doi:10.1212/WNL.0000000000000717
    1. Montero-Odasso MM, Barnes B, Speechley M, et al. Disentangling cognitive-frailty: results from the Gait and Brain Study. J Gerontol A Biol Sci Med Sci. 2016;71:1476–1482. doi:10.1093/gerona/glw044
    1. Muir SW, Speechley M, Wells J, Borrie M, Gopaul K, Montero-Odasso M. Gait assessment in mild cognitive impairment and Alzheimer’s disease: the effect of dual-task challenges across the cognitive spectrum. Gait Posture. 2012;35:96–100. doi:10.1016/j.gaitpost.2011.08.014
    1. Verghese J, Wang C, Lipton RB, Holtzer R, Xue X. Quantitative gait dysfunction and risk of cognitive decline and dementia. J Neurol Neurosurg Psychiatry. 2007;78:929–935. doi:10.1136/jnnp.2006.106914
    1. Farrer LA, Cupples LA, Haines JL, et al. Effects of age, sex, and ethnicity on the association between apolipoprotein E genotype and Alzheimer disease. A meta-analysis. APOE and Alzheimer Disease Meta Analysis Consortium. JAMA. 1997;278:1349–1356. doi:10.1001/jama.1997.03550160069041
    1. Scarabino D, Broggio E, Gambina G, Maida C, Gaudio MR, Corbo RM. Apolipoprotein E genotypes and plasma levels in mild cognitive impairment conversion to Alzheimer’s disease: a follow-up study. Am J Med Genet B Neuropsychiatr Genet. 2016;171:1131–1138. doi:10.1002/ajmg.b.32495
    1. Liu CC, Liu CC, Kanekiyo T, Xu H, Bu G. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9:106–118. doi:10.1038/nrneurol.2012.263
    1. Montero-Odasso M, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition: a complementary approach to understanding brain function and the risk of falling. J Am Geriatr Soc. 2012;60:2127–2136. doi:10.1111/j.1532-5415.2012.04209.x
    1. Sakurai R, Fujiwara Y, Yasunaga M, et al. Regional cerebral glucose metabolism and gait speed in healthy community-dwelling older women. J Gerontol A Biol Sci Med Sci. 2014;69:1519–1527. doi:10.1093/gerona/glu093
    1. Hooghiemstra AM, Ramakers IH, Sistermans N, et al. Gait speed and grip strength reflect cognitive impairment and are modestly related to incident cognitive decline in memory clinic patients with subjective cognitive decline and mild cognitive impairment: findings from the 4C study. J Gerontol A Biol Sci Med Sci. 2017. doi:10.1093/gerona/glx003
    1. Verghese J, Holtzer R, Wang C, Katz MJ, Barzilai N, Lipton RB. Role of APOE genotype in gait decline and disability in aging. J Gerontol A Biol Sci Med Sci. 2013;68:1395–1401. doi:10.1093/gerona/glt115
    1. Buchman AS, Boyle PA, Wilson RS, Beck TL, Kelly JF, Bennett DA. Apolipoprotein E e4 allele is associated with more rapid motor decline in older persons. Alzheimer Dis Assoc Disord. 2009;23:63–69. doi:10.1097/WAD.0b013e31818877b5
    1. MacAulay RK, Allaire T, Brouillette R, Foil H, Bruce-Keller AJ, Keller JN. Apolipoprotein E genotype linked to spatial gait characteristics: predictors of cognitive dual task gait change. PLoS One. 2016;11:e0156732. doi:10.1371/journal.pone.0156732
    1. Doi T, Shimada H, Makizako H, Tsutsumimoto K, Uemura K, Suzuki T. ApolipoproteinE genotype and physical function among older people with mild cognitive impairment. Geriatr Gerontol Int. 2015;15:422–427. doi:10.1111/ggi.12291
    1. Montero-Odasso M, Casas A, Hansen KT, et al. Quantitative gait analysis under dual-task in older people with mild cognitive impairment: a reliability study. J Neuroeng Rehabil. 2009;6:35. doi:10.1186/ 1743-0003-6-35
    1. Robertson DA, Savva GM, Coen RF, Kenny RA. Cognitive function in the prefrailty and frailty syndrome. J Am Geriatr Soc. 2014;62:2118–2124. doi:10.1111/jgs.13111
    1. Petersen RC. Clinical practice. Mild cognitive impairment. N Engl J Med. 2011;364:2227–2234. doi:10.1056/NEJMcp0910237
    1. Winblad B, Palmer K, Kivipelto M, et al. Mild cognitive impairment–beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment. J Intern Med. 2004;256:240–246. doi:10.1111/j.1365-2796.2004.01380.x
    1. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189–198.
    1. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53:695–699. doi:10.1111/j.1532-5415.2005.53221.x
    1. Montero-Odasso M, Muir SW. Simplifying detection of mild cognitive impairment subtypes. J Am Geriatr Soc. 2010;58:992–994. doi:10.1111/j.1532-5415.2010.02823.x
    1. Hausdorff JM. Gait variability: methods, modeling and meaning. J Neuroeng Rehabil. 2005;2:19. doi:10.1186/1743-0003-2-19
    1. Hausdorff JM. Gait dynamics, fractals and falls: finding meaning in the stride-to-stride fluctuations of human walking. Hum Mov Sci. 2007;26:555–589. doi:10.1016/j.humov.2007.05.003
    1. Hausdorff JM, Cudkowicz ME, Firtion R, Wei JY, Goldberger AL. Gait variability and basal ganglia disorders: stride-to-stride variations of gait cycle timing in Parkinson’s disease and Huntington’s disease. Mov Disord. 1998;13:428–437. doi:10.1002/mds.870130310
    1. Lord S, Howe T, Greenland J, Simpson L, Rochester L. Gait variability in older adults: a structured review of testing protocol and clinimetric properties. Gait Posture. 2011;34:443–450. doi:10.1016/j.gaitpost.2011.07.010
    1. Montero-Odasso M. Gait as a biomarker of cognitive impairment and dementia syndromes. Quo vadis? Eur J Neurol. 2016;23:437–438. doi:10.1111/ene.12908
    1. Annweiler C, Montero-Odasso M, Bartha R, Drozd J, Hachinski V, Beauchet O. Association between gait variability and brain ventricle attributes: a brain mapping study. Exp Gerontol. 2014;57:256–263. doi:10.1016/j.exger.2014.06.015
    1. Annweiler C, Beauchet O, Bartha R, et al. Motor cortex and gait in mild cognitive impairment: a magnetic resonance spectroscopy and volumetric imaging study. Brain. 2013;136:859–871. doi:10.1093/brain/aws373
    1. Rosano C, Brach J, Studenski S, Longstreth WT, Jr, Newman AB. Gait variability is associated with subclinical brain vascular abnormalities in high-functioning older adults. Neuroepidemiology. 2007;29:193–200. doi:10.1159/000111582
    1. Song Y, Stampfer MJ, Liu S. Meta-analysis: apolipoprotein E genotypes and risk for coronary heart disease. Ann Intern Med. 2004;141:137–147.
    1. Brickman AM, Schupf N, Manly JJ, et al. APOE ε4 and risk for Alzheimer’s disease: do regionally distributed white matter hyperintensities play a role? Alzheimers Dement. 2014;10:619–629. doi:10.1016/j.jalz.2014.07.155
    1. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropathology, including Alzheimer’s disease. Proc Natl Acad Sci USA. 2006;103:5644–5651. doi:10.1073/pnas.0600549103
    1. Horoupian DS, Wasserstein PH. Alzheimer’s disease pathology in motor cortex in dementia with Lewy bodies clinically mimicking corticobasal degeneration. Acta Neuropathol. 1999;98:317–322. doi:10.1007/s004010051087
    1. Schneider JA, Li JL, Li Y, Wilson RS, Kordower JH, Bennett DA. Substantia nigra tangles are related to gait impairment in older persons. Ann Neurol. 2006;59:166–173. doi:10.1002/ana.20723
    1. Wolf DS, Gearing M, Snowdon DA, Mori H, Markesbery WR, Mirra SS. Progression of regional neuropathology in Alzheimer disease and normal elderly: findings from the Nun study. Alzheimer Dis Assoc Disord. 1999;13:226–231.
    1. Skoog I, Hörder H, Frändin K, et al. Association between APOE genotype and change in physical function in a population-based Swedish cohort of older individuals followed over four years. Front Aging Neurosci. 2016;8:225. doi:10.3389/fnagi.2016.00225
    1. Vasunilashorn S, Glei DA, Lin YH, Goldman N. Apolipoprotein E and measured physical and pulmonary function in older Taiwanese adults. Biodemography Soc Biol. 2013;59:57–67. doi:10.1080/19485565.2013.778703
    1. Alfred T, Ben-Shlomo Y, Cooper R, et al. ; HALCyon Study Team Associations between APOE and low-density lipoprotein cholesterol genotypes and cognitive and physical capability: the HALCyon programme. Age (Dordr). 2014;36:9673. doi:10.1007/s11357-014-9673-9
    1. Melzer D, Dik MG, van Kamp GJ, Jonker C, Deeg DJ. The apolipoprotein E e4 polymorphism is strongly associated with poor mobility performance test results but not self-reported limitation in older people. J Gerontol A Biol Sci Med Sci. 2005;60:1319–1323.
    1. Caselli RJ, Reiman EM, Locke DE, et al. Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment. Arch Neurol. 2007;64:1306–1311. doi:10.1001/archneur.64.9.1306
    1. Wisdom NM, Callahan JL, Hawkins KA. The effects of apolipoprotein E on non-impaired cognitive functioning: a meta-analysis. Neurobiol Aging. 2011;32:63–74. doi:10.1016/j.neurobiolaging.2009.02.003
    1. Spampinato MV, Langdon BR, Patrick KE, Parker RO, Collins H, Pravata’ E; Alzheimer’s Disease Neuroimaging Initiative Gender, apolipoprotein E genotype, and mesial temporal atrophy: 2-year follow-up in patients with stable mild cognitive impairment and with progression from mild cognitive impairment to Alzheimer’s disease. Neuroradiology. 2016;58:1143–1151. doi:10.1007/s00234-016-1740-8
    1. Shi J, Leporé N, Gutman BA, et al. ; Alzheimer’s Disease Neuroimaging Initiative Genetic influence of apolipoprotein E4 genotype on hippocampal morphometry: An N = 725 surface-based Alzheimer’s disease neuroimaging initiative study. Hum Brain Mapp. 2014;35:3903–3918. doi:10.1002/hbm.22447
    1. Elias-Sonnenschein LS, Viechtbauer W, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia: a meta-analysis. J Neurol Neurosurg Psychiatry. 2011;82:1149–1156. doi:10.1136/jnnp.2010.231555

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa